The Center for Cancer Immunology is dedicated to learning how to activate the immune system to target and destroy cancer within the body. Give today to help us revolutionize the way we treat cancer – not just at Mass General, but also worldwide. Make a gift.
For additional information about how you can support this program, call 617-726-2200.
Explore the Center for Cancer Immunology
Overview
We are in the midst of a revolution in the treatment of cancer. By harnessing and enhancing the body’s immune system, we can reduce tumor burden in patients and, in a subset of patients and cancers, achieve long-lasting remission. This has led to FDA approval of immune-based treatments for melanoma, lung cancer and kidney cancer – with many more cancers soon to be impacted. As these treatments become the standard of care, we can say with increasing certainty that the era of cancer immunotherapy has begun.
And yet, even as we are seeing some patients being cured by these new immunotherapies, most patients remain unresponsive. To accelerate and expand this ongoing revolution, we need to understand what drives immune responses against a tumor; determine why some patients experience effective immune responses while others do not; develop and bring safe and effective immunotherapies to patients; and invent completely new immune-based therapeutic strategies.
A New Era for Cancer Treatment
The Center for Cancer Immunology at the Mass General Cancer Center addresses these challenges. Our achievements over the past decade at the Henri and Belinda Termeer Center for Targeted Therapies in understanding targeted cancer therapies and bringing them to patients provides a model for the seamless integration of basic research, translational sciences, clinical trials and patient care. Working closely with the leaders of the Termeer Center, physicians and scientists throughout Mass General and the Cancer Center, faculty at the Center for Cancer Immunology are working to advance our understanding of cancer immunity and harness the immune system to cure cancer.
Program Areas
Team members in the Center for Cancer Immunology are working creatively and passionately to understand the rules of the game for tumor immunity, to develop new and potent immunotherapies, and ultimately, to use the immune system as a powerful tool to prevent cancer progression. To do this, we have chosen to focus our efforts on four transformative programs: cellular immunotherapy, checkpoint inhibitors, cancer vaccines, and early cancer immunotherapy. With a world-class team and an extensive research and clinical infrastructure in place, we are ready to accelerate the delivery of these potentially lifesaving therapies to our patients and set new standards of care that will benefit patients worldwide.
A Collaborative Effort
See how the Center for Cancer Immunology leverages the expertise of a variety of internal and external resources.
1
of
1
Meet the Team
The Center for Cancer Immunology’s core faculty, Nir Hacohen, PhD, Marcela Maus, MD, PhD and Shawn Demehri, MD, PhD work closely with physicians and scientists throughout Mass General and the Cancer Center.
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
Mass General Cancer Center's Dr. Nir Hacohen sits down with Kiss 108's Billy Costa to discuss a researchers perspective of immuno-oncology and how it has impacted patients.
Dr. Shawn Demehri summarizes his presentation that was given on May 17, 2019 at the Annual Advances in Cancer Immunotherapy CME Course. He presented on innate immunity in cancer immunotherapy.
Justin Gainor, MD and Nir Hacohen, PhD describe how researchers here at the Center for Cancer Immunology are activating the human immune system to target cancer within the body.
Kiss 108 FM’s Billy Costa talks with four experts from the Mass General Cancer Center to learn about what CAR T-cell therapy is and what impact it has on both patients and the medical community.
Jonathan Chen, MD, PhD, and Nir Hacohen, PhD, are co-authors of a recently published study in Nature Immunology, Human Lung Cancer Harbors Spatially-organized Stem-immunity Hubs Associated with Response to Immunotherapy.
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
Learn more about the findings and importance of a study led by a research and clinical team from the Mass General Cancer Center who is developing new cell therapy for patients with recurrent glioblastoma.
1of
3
Contact the Cancer Center
Contact the Mass General Cancer Center to make an appointment or learn more about our programs.